The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, SPWR and LCID

NEW YORK, NY / ACCESSWIRE / April 11, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline: April 11, 2022

Fennec Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in FENC: https://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?id=25815&from=1

SunPower Corporation (NASDAQ:SPWR)
Class Period: August 3, 2021 – January 20, 2022
Lead Plaintiff Deadline: April 18, 2022

The complaint alleges SunPower Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) certain connectors used by SunPower suffered from cracking issues; (2) as a result, the Company was reasonably likely to incur costs to remediate the faulty connectors; (3) as a result of the foregoing, SunPower’s financial results would be adversely impacted; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SPWR: https://www.kleinstocklaw.com/pslra-1/sunpower-corporation-loss-submission-form?id=25815&from=1

Lucid Group, Inc. (NASDAQ:LCID)
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
Lead Plaintiff Deadline: May 31, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid’s business and operations. Specifically, the Company overstated its production capabilities while concealing that “extraordinary supply chain and logistics challenges” were hampering Lucid’s operations. As a result of the defendants’ wrongful acts and omissions, and the significant decline in the market value of Lucid’s common stock, Lucid investors have suffered significant damages.

Learn about your recoverable losses in LCID: https://www.kleinstocklaw.com/pslra-1/lucid-group-inc-loss-submission-form?id=25815&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE : The Klein Law Firm

View source version on accesswire.com:
https://www.accesswire.com/696928/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FENC-SPWR-and-LCID

If You Liked This Article Click To Share

Biotech